Undesirable Long-Term Outcome of Entecavir Therapy in Chronic Hepatitis B With Cirrhosis

The large study of Hou et  al1 is interesting and has provided important information on nucleos(t)ide analogue (Nuc) therapy up to 10 years in chronic hepatitis B virus (HBV) infection. The authors are to be commended for conducting such a well-designed study, with stringent definitions of clinical outcome events (COE), to confirm the long-term efficacy and safety of entecavir (ETV) therapy in chronic HBV infection. However, some important data of this study were not utilized for additional or further analyses and discussion.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research